{"id":417,"date":"2019-02-26T18:03:49","date_gmt":"2019-02-26T09:03:49","guid":{"rendered":"http:\/\/slfn11.iab.keio.ac.jp\/?page_id=417"},"modified":"2023-11-09T14:00:28","modified_gmt":"2023-11-09T05:00:28","slug":"home-en","status":"publish","type":"page","link":"https:\/\/slfn11.iab.keio.ac.jp\/?page_id=417","title":{"rendered":"Home"},"content":{"rendered":"\n<h1 class=\"wp-block-heading has-text-align-center\">Welcome to my HP! \u3000<\/h1>\n\n\n<figure class=\"wp-block-image alignright is-resized\"><img decoding=\"async\" class=\"wp-image-7\" style=\"width: 301px; height: 301px;\" src=\"https:\/\/slfn11.iab.keio.ac.jp\/wp-content\/uploads\/2019\/02\/Murai-molCell_Final_V3-1024x1024.jpg\" alt=\"\" \/>\n<figcaption class=\"wp-element-caption\">SLFN11 blocks stressed replication<\/figcaption>\n<\/figure>\n\n<p style=\"text-align: left;\">I started working\u00a0at Institution of Advanced Bioscience (IAB), Keio University in October 2018. Great interests of my research are DNA damage, DNA repair and drug resistance in cancer therapy. In these years, I have contributed the clinical development of PARP inhibitors through revealing the additional mechanisms of action named PARP-trapping. <a href=\"https:\/\/slfn11.iab.keio.ac.jp\/?page_id=423\">Schlafen 11 (SLFN11)<\/a>, the lifework gene for me, is more than curious because SLFN11 greatly increases the anti-tumor activity of various DNA-targeting drugs. Here at IAB, I intensively work on to fully understand the functions of <a href=\"https:\/\/slfn11.iab.keio.ac.jp\/?page_id=423\">SLFN11<\/a> as well as to develop the utility of SLFN11 in the clinic as a predictive biomarker of drug sensitivity.<\/p>\n\n\n<h2 class=\"wp-block-heading\"><a href=\"https:\/\/slfn11.iab.keio.ac.jp\/?page_id=420\">About <\/a><a href=\"https:\/\/slfn11.iab.keio.ac.jp\/?page_id=420\">Junko<\/a><a href=\"https:\/\/slfn11.iab.keio.ac.jp\/?page_id=420\"> Murai<\/a><\/h2>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Welcome to my HP! \u3000 SLFN11 blocks stressed replication I started working\u00a0at Institution of Advanced Bioscience (IAB), Keio University in October 2018. Great interests of my research are DNA damage, DNA repair and drug resistance in cancer therapy. In these years, I have contributed the clinical development of PARP inhibitors through revealing the additional mechanisms &hellip; <a href=\"https:\/\/slfn11.iab.keio.ac.jp\/?page_id=417\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_locale":"en_US","_original_post":"2"},"_links":{"self":[{"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/417"}],"collection":[{"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=417"}],"version-history":[{"count":26,"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/417\/revisions"}],"predecessor-version":[{"id":1171,"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/417\/revisions\/1171"}],"wp:attachment":[{"href":"https:\/\/slfn11.iab.keio.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}